Assessed for eligibility (n=51)

*ITT & safety population:* All eligible patients who received study drug at least once *(n=48)*

*PP population:* All patients who underwent response evaluation at least once *(n=37)*

Excluded (n=11)

* Fatigue (n=4)
* Withdrawal of consent (n=2)
* Biliary sepsis (n=2)
* Death due to septic shock (n=1)
* Acute cerebral infarction (n=1)
* Irinotecan induced encephalopathy (n=1)

Excluded (n=3)

* Did not meet eligibility criteria (n=1)
* Withdrawal of consent (n=2)

**Supplementary figure 1:** Trial flowchart

**Supplementary Table 1.** QoL: EORTC QLQ-C30 and QLQ-PAN26 (QoL analysis of all available patients, N = 31)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 　 | Baseline | Last | Change | *p* |
| Mean ±SD | Median | Min | Max | Mean ±SD | Median | Min | Max | Mean ±SD | Median | Min | Max |
| EORTC QLQ-C30 (N = 31) |
| **Global health status / QoL** | 45.43 ± 22.88 | 41.67 | 0.00 | 83.33 | 48.66 ± 24.14 | 50.00 | 0.00 | 100.00 | 3.23 ± 29.07 | 0.00 | -58.33 | 91.67 | 0.548§ |
| **Functional scales** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Physical functioning | 71.18 ± 22.62 | 73.33 | 26.67 | 100.00 | 63.01 ± 29.03 | 66.67 | 0.00 | 100.00 | -8.17 ± 24.81 | -6.67 | -66.67 | 40.00 | 0.081§ |
| Role functioning | 67.20 ± 24.86 | 66.67 | 0.00 | 100.00 | 54.84 ± 32.84 | 66.67 | 0.00 | 100.00 | -12.37 ± 32.23 | -16.67 | -83.33 | 66.67 | **0.044§** |
| Emotional functioning | 69.89 ± 20.27 | 75.00 | 25.00 | 100.00 | 67.74 ± 30.65 | 75.00 | 0.00 | 100.00 | -2.15 ± 31.68 | 0.00 | -66.67 | 58.33 | 0.713§ |
| Cognitive functioning | 81.72 ± 17.12 | 83.33 | 33.33 | 100.00 | 70.97 ± 30.22 | 83.33 | 0.00 | 100.00 | -10.75 ± 26.28 | 0.00 | -83.33 | 33.33 | **0.015\*** |
| Social functioning | 60.75 ± 28.88 | 66.67 | 0.00 | 100.00 | 66.13 ± 31.53 | 66.67 | 0.00 | 100.00 | 5.38 ± 24.46 | 0.00 | -33.33 | 66.67 | 0.238§ |
| **Symptom scales** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Fatigue | 39.07 ± 23.59 | 33.33 | 0.00 | 100.00 | 50.18 ± 27.92 | 44.44 | 11.11 | 100.00 | 11.11 ± 25.08 | 11.11 | -44.44 | 66.67 | **0.021§** |
| Nausea and vomiting | 16.13 ± 17.19 | 16.67 | 0.00 | 66.67 | 25.81 ± 34.35 | 0.00 | 0.00 | 100.00 | 9.68 ± 29.57 | 0.00 | -33.33 | 83.33 | 0.131\* |
| Pain  | 32.80 ± 29.48 | 16.67 | 0.00 | 100.00 | 37.63 ± 34.38 | 33.33 | 0.00 | 100.00 | 4.84 ± 39.76 | 0.00 | -66.67 | 83.33 | 0.510§ |
| Dyspnoea | 17.20 ± 18.69 | 0.00 | 0.00 | 66.67 | 27.96 ± 37.00 | 33.33 | -33.33 | 100.00 | 10.75 ± 28.57 | 0.00 | -66.67 | 66.67 | **0.038\*** |
| Constipation  | 33.33 ± 28.08 | 33.33 | 0.00 | 100.00 | 31.18 ± 32.72 | 33.33 | 0.00 | 100.00 | -2.15 ± 25.31 | 0.00 | -66.67 | 66.67 | 0.661\* |
| Diarrhoea  | 18.28 ± 26.56 | 0.00 | 0.00 | 100.00 | 19.35 ± 30.26 | 0.00 | 0.00 | 100.00 | 1.08 ± 36.40 | 0.00 | -66.67 | 100.00 | 0.873\* |
| Insomnia | 26.88 ± 31.02 | 33.33 | 0.00 | 100.00 | 35.48 ± 34.84 | 33.33 | 0.00 | 100.00 | 8.60 ± 40.58 | 0.00 | -66.67 | 100.00 | 0.374\* |
| Appetite loss | 44.09 ± 38.23 | 33.33 | 0.00 | 100.00 | 37.63 ± 36.65 | 33.33 | 0.00 | 100.00 | -6.45 ± 40.09 | 0.00 | -100.00 | 66.67 | 0.310\* |
| Financial difficulties | 33.33 ± 32.79 | 33.33 | 0.00 | 100.00 | 34.41 ± 34.37 | 33.33 | 0.00 | 100.00 | 1.08 ± 32.22 | 0.00 | -66.67 | 66.67 | 0.484\* |
| EORTC QLQ-PAN26 (N = 31) |
| **Symptom scales** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Pancreatic pain | 29.57 ± 23.55 | 25.00 | 0.00 | 100.00 | 29.84 ± 27.25 | 33.33 | 0.00 | 100.00 | 0.27 ± 28.20 | 0.00 | -58.33 | 91.67 | 0.614\* |
| Bloating | 26.88 ± 25.99 | 33.33 | 0.00 | 66.67 | 36.56 ± 35.27 | 33.33 | 0.00 | 100.00 | 9.68 ± 31.90 | 0.00 | -33.33 | 100.00 | 0.202\* |
| Digestive symptoms | 32.26 ± 28.38 | 33.33 | 0.00 | 100.00 | 42.47 ± 31.06 | 33.33 | 0.00 | 100.00 | 10.22 ± 27.00 | 0.00 | -50.00 | 83.33 | 0.069\* |
| Taste | 32.26 ± 27.41 | 33.33 | 0.00 | 100.00 | 38.71 ± 30.64 | 33.33 | 0.00 | 100.00 | 6.45 ± 29.84 | 0.00 | -66.67 | 66.67 | 0.274\* |
| Indigestion | 35.48 ± 29.25 | 33.33 | 0.00 | 100.00 | 34.41 ± 31.09 | 33.33 | 0.00 | 100.00 | -1.08 ± 35.40 | 0.00 | -100.00 | 66.67 | 0.916\* |
| Flatulence | 29.03 ± 25.03 | 33.33 | 0.00 | 66.67 | 31.18 ± 32.72 | 33.33 | 0.00 | 100.00 | 2.15 ± 36.84 | 0.00 | -66.67 | 100.00 | 0.794\* |
| Weight loss | 21.51 ± 33.39 | 0.00 | 0.00 | 100.00 | 20.43 ± 34.58 | 0.00 | 0.00 | 100.00 | -1.08 ± 48.99 | 0.00 | -100.00 | 100.00 | 0.909\* |
| Weakness arms and legs | 37.63 ± 29.01 | 33.33 | 0.00 | 100.00 | 36.56 ± 34.24 | 33.33 | 0.00 | 100.00 | -1.08 ± 37.37 | 0.00 | -100.00 | 66.67 | 0.728\* |
| Dry mouth | 26.88 ± 24.57 | 33.33 | 0.00 | 100.00 | 44.09 ± 33.21 | 33.33 | 0.00 | 100.00 | 17.20 ± 32.65 | 0.00 | -33.33 | 100.00 | **0.011\*** |
| Hepatic symptoms | 16.13 ± 17.19 | 16.67 | 0.00 | 50.00 | 15.59 ± 18.42 | 16.67 | 0.00 | 66.67 | -0.54 ± 19.62 | 0.00 | -50.00 | 33.33 | 0.866\* |
| Altered bowel habit | 29.57 ± 24.58 | 33.33 | 0.00 | 100.00 | 25.27 ± 25.35 | 16.67 | 0.00 | 100.00 | -4.30 ± 23.56 | 0.00 | -83.33 | 50.00 | 0.341\* |
| Body image | 46.24 ± 32.44 | 33.33 | 0.00 | 100.00 | 47.85 ± 32.45 | 33.33 | 0.00 | 100.00 | 1.61 ± 34.48 | 0.00 | -100.00 | 66.67 | 0.827\* |
| Troubled with side-effects | 43.01 ± 29.57 | 33.33 | 0.00 | 100.00 | 52.69 ± 29.05 | 33.33 | 0.00 | 100.00 | 9.68 ± 34.07 | 0.00 | -66.67 | 66.67 | 0.239\* |
| Future Worries | 63.44 ± 25.90 | 66.67 | 33.33 | 100.00 | 51.61 ± 30.34 | 33.33 | 0.00 | 100.00 | -11.83 ± 35.47 | 0.00 | -100.00 | 66.67 | 0.055\* |
| Planning of activities | 49.46 ± 31.53 | 33.33 | 0.00 | 100.00 | 37.63 ± 35.66 | 33.33 | 0.00 | 100.00 | -11.80 ± 40.20 | 0.00 | -100.00 | 66.67 | 0.108\* |
| **Functional scales** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Satisfaction with health care | 50.00 ± 34.13 | 33.33 | 0.00 | 100.00 | 59.68 ± 34.33 | 66.67 | 0.00 | 100.00 | 9.68 ± 37.57 | 0.00 | -66.67 | 100.00 | 0.169§ |
| Sexuality | 59.68 ± 39.43 | 66.67 | 0.00 | 100.00 | 56.99 ± 38.28 | 66.67 | 0.00 | 100.00 | -2.69 ± 55.37 | 0.00 | -100.00 | 100.00 | 0.792§ |

Change, Last visit – Baseline visit (visit 2). QoL, quality of life; EORTC, European Organization for Research and Treatment of Cancer; QLQ-C30, Quality of Life Questionnaire Core 30; QLQ-PAN26, Quality of Life Questionnaire pancreatic cancer module 26; SD, standard deviation; Min, minimum; Max, maximum. § Paired t-test. \* Wilcoxon signed rank test.

**Supplementary table 2**. QoL: EORTC QLQ-C30 and QLQ-PAN26 (QoL analysis of patients who showed disease control, N = 29)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 　 | Baseline | Last | Change | *p* |
| Mean ±SD | Median | Min | Max | Mean ±SD | Median | Min | Max | Mean ±SD | Median | Min | Max |
| EORTC QLQ-C30 (N = 29) |
| **Global health status / QoL** | 45.69 ± 23.53 | 41.67  | 0.00  | 83.33  | 50.29 ± 23.21 | 50.00  | 0.00  | 100.00  | 4.6 ± 29.25 | 8.33  | -58.33  | 91.67  | 0.412§ |
| **Functional scales** | 　 |  |  | 　 | 　 |  |  | 　 | 　 |  |  | 　 |  |
| Physical functioning | 72.18 ± 23.03 | 80.00  | 26.67  | 100.00  | 64.6 ± 27.41 | 66.67  | 0.00  | 100.00  | -7.59 ± 23.67 | -6.67  | -66.67  | 40.00  | 0.181\* |
| Role functioning | 66.09 ± 24.95 | 66.67  | 0.00  | 100.00  | 55.75 ± 31.95 | 66.67  | 0.00  | 100.00  | -10.34 ± 31.69 | -16.67  | -83.33  | 66.67  | 0.095§ |
| Emotional functioning | 69.54 ± 20.79 | 75.00  | 25.00  | 100.00  | 69.25 ± 28.71 | 75.00  | 0.00  | 100.00  | -0.29 ± 30.36 | 0.00  | -66.67  | 58.33  | 0.960§ |
| Cognitive functioning | 81.03 ± 17.36 | 83.33  | 33.33  | 100.00  | 72.99 ± 28.17 | 83.33  | 0.00  | 100.00  | -8.05 ± 23.42 | 0.00  | -66.67  | 33.33  | **0.040\*** |
| Social functioning | 59.2 ± 28.9 | 66.67  | 0.00  | 100.00  | 63.79 ± 31.28 | 66.67  | 0.00  | 100.00  | 4.6 ± 24.72 | 0.00  | -33.33  | 66.67  | 0.333§ |
| **Symptom scales** | 　 |  |  | 　 | 　 |  |  | 　 | 　 |  |  | 　 |  |
| Fatigue | 39.46 ± 23.63 | 33.33  | 0.00  | 100.00  | 49.43 ± 26.84 | 44.44  | 11.11  | 100.00  | 9.96 ± 25.16 | 11.11  | -44.44  | 66.67  | **0.045§** |
| Nausea and vomiting | 14.37 ± 14.99 | 16.67  | 0.00  | 50.00  | 22.99 ± 32.58 | 0.00  | 0.00  | 100.00  | 8.62 ± 30.2 | 0.00  | -33.33  | 83.33  | 0.184\* |
| Pain  | 32.76 ± 30.16 | 16.67  | 0.00  | 100.00  | 35.63 ± 33.54 | 33.33  | 0.00  | 100.00  | 2.87 ± 40.13 | 0.00  | -66.67  | 83.33  | 0.708§ |
| Dyspnoea | 17.24 ± 18.82 | 0.00  | 0.00  | 66.67  | 26.44 ± 35.43 | 33.33  | -33.33  | 100.00  | 9.2 ± 27.54 | 0.00  | -66.67  | 66.67  | 0.070\* |
| Constipation  | 33.33 ± 29.03 | 33.33  | 0.00  | 100.00  | 28.74 ± 31.23 | 33.33  | 0.00  | 100.00  | -4.6 ± 22.7 | 0.00  | -66.67  | 33.33  | 0.318\* |
| Diarrhoea  | 16.09 ± 25.7 | 0.00  | 0.00  | 100.00  | 17.24 ± 27.15 | 0.00  | 0.00  | 100.00  | 1.15 ± 33.31 | 0.00  | -66.67  | 100.00  | 0.936\* |
| Insomnia | 26.44 ± 30.8 | 33.33  | 0.00  | 100.00  | 33.33 ± 33.9 | 33.33  | 0.00  | 100.00  | 6.9 ± 37.53 | 0.00  | -66.67  | 100.00  | 0.473\* |
| Appetite loss | 42.53 ± 39.05 | 33.33  | 0.00  | 100.00  | 35.63 ± 36.02 | 33.33  | 0.00  | 100.00  | -6.9 ± 40.48 | 0.00  | -100.00  | 66.67  | 0.360\* |
| Financial difficulties | 33.33 ± 33.9 | 33.33  | 0.00  | 100.00  | 35.63 ± 34.94 | 33.33  | 0.00  | 100.00  | 2.3 ± 32.67 | 0.00  | -66.67  | 66.67  | 0.400\* |
| EORTC QLQ-PAN26 (N = 29) |
| **Symptom scales** | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 | 　 |  |
| Pancreatic pain | 29.89 ± 24.32 | 25.00  | 0.00  | 100.00  | 28.45 ± 26.85 | 33.33  | 0.00  | 100.00  | -1.44 ± 27.6 | 0.00  | -58.33  | 91.67  | 0.369\* |
| Bloating | 26.44 ± 25.34 | 33.33  | 0.00  | 66.67  | 34.48 ± 34.44 | 33.33  | 0.00  | 100.00  | 8.05 ± 27.2 | 0.00  | -33.33  | 100.00  | 0.175\* |
| Digestive symptoms | 31.61 ± 28.48 | 33.33  | 0.00  | 100.00  | 40.8 ± 30.19 | 33.33  | 0.00  | 100.00  | 9.2 ± 22.99 | 0.00  | -50.00  | 50.00  | **0.048\*** |
| Taste | 32.18 ± 28.34 | 33.33  | 0.00  | 100.00  | 36.78 ± 29.48 | 33.33  | 0.00  | 100.00  | 4.6 ± 28.67 | 0.00  | -66.67  | 66.67  | 0.450\* |
| Indigestion | 35.63 ± 30.24 | 33.33  | 0.00  | 100.00  | 32.18 ± 29.66 | 33.33  | 0.00  | 100.00  | -3.45 ± 34.29 | 0.00  | -100.00  | 66.67  | 0.812\* |
| Flatulence | 28.74 ± 25.86 | 33.33  | 0.00  | 66.67  | 31.03 ± 33.83 | 33.33  | 0.00  | 100.00  | 2.3 ± 38.09 | 0.00  | -66.67  | 100.00  | 0.794\* |
| Weight loss | 22.99 ± 34.02 | 0.00  | 0.00  | 100.00  | 18.39 ± 32.27 | 0.00  | 0.00  | 100.00  | -4.6 ± 46.92 | 0.00  | -100.00  | 100.00  | 0.591\* |
| Weakness arms and legs | 37.93 ± 29.97 | 33.33  | 0.00  | 100.00  | 35.63 ± 32.67 | 33.33  | 0.00  | 100.00  | -2.3 ± 36.02 | 0.00  | -100.00  | 66.67  | 0.532\* |
| Dry mouth | 27.59 ± 24.87 | 33.33  | 0.00  | 100.00  | 42.53 ± 32.63 | 33.33  | 0.00  | 100.00  | 14.94 ± 32.27 | 0.00  | -33.33  | 100.00  | **0.026\*** |
| Hepatic symptoms | 16.67 ± 17.51 | 16.67  | 0.00  | 50.00  | 16.09 ± 18.82 | 16.67  | 0.00  | 66.67  | -0.57 ± 20.29 | 0.00  | -50.00  | 33.33  | 0.866\* |
| Altered bowel habit | 28.16 ± 24.8 | 16.67  | 0.00  | 100.00  | 24.14 ± 25.74 | 16.67  | 0.00  | 100.00  | -4.02 ± 24.23 | 0.00  | -83.33  | 50.00  | 0.435\* |
| Body image | 48.28 ± 32.27 | 33.33  | 0.00  | 100.00  | 47.7 ± 30.86 | 33.33  | 0.00  | 100.00  | -0.57 ± 33.47 | 0.00  | -100.00  | 66.67  | 0.887\* |
| Troubled with side-effects | 44.83 ± 29.39 | 33.33  | 0.00  | 100.00  | 52.87 ± 29.71 | 33.33  | 0.00  | 100.00  | 8.05 ± 33.51 | 0.00  | -66.67  | 66.67  | 0.372\* |
| Future Worries | 63.22 ± 25.29 | 66.67  | 33.33  | 100.00  | 50.57 ± 29.84 | 33.33  | 0.00  | 100.00  | -12.64 ± 32.06 | 0.00  | -100.00  | 66.67  | **0.026\*** |
| Planning of activities | 50.57 ± 31.1 | 33.33  | 0.00  | 100.00  | 36.78 ± 34.29 | 33.33  | 0.00  | 100.00  | -13.79 ± 40.61 | 0.00  | -100.00  | 66.67  | 0.085\* |
| **Functional scales** | 　 |  |  | 　 | 　 |  |  | 　 | 　 |  |  | 　 |  |
| Satisfaction with health care | 46.55 ± 32.57 | 33.33  | 0.00  | 100.00  | 56.9 ± 33.77 | 66.67  | 0.00  | 100.00  | 10.34 ± 38.76 | 0.00  | -66.67  | 100.00  | 0.169§ |
| Sexuality | 63.79 ± 37.41 | 66.67  | 0.00  | 100.00  | 55.17 ± 38.68 | 50.00  | 0.00  | 100.00  | -8.62 ± 52.09 | 0.00  | -100.00  | 100.00  | 0.389§ |

Change, Last visit – Baseline visit (visit 2). QOL, quality of life; EORTC, European Organization for Research and Treatment of Cancer; QLQ-C30, Quality of Life Questionnaire Core 30; QLQ-PAN26, Quality of Life Questionnaire pancreatic cancer module 26; SD, standard deviation; Min, minimum; Max, maximum. § Paired t-test. \* Wilcoxon signed rank test.

**Supplementary table 3**. QoL: EORTC QLQ-C30 and QLQ-PAN26 (QoL analysis of patients who received more than 15 cycles, N = 15)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 　 | Baseline | Last | Change | *p* |
| Mean ±SD | Median | Min | Max | Mean ±SD | Median | Min | Max | Mean ±SD | Median | Min | Max |
| EORTC QLQ-C30 (N = 15) |
| **Global health status / QoL** | 48.89 ± 20.15 | 41.67  | 25.00  | 83.33  | 47.78 ± 17.86 | 50.00  | 8.33  | 83.33  | -1.11 ± 22.12 | 8.33  | -58.33  | 25.00  | 0.854§ |
| **Functional scales** |  |  |  | 　 |  |  |  | 　 |  |  |  | 　 |  |
| Physical functioning | 72.89 ± 23.53 | 80.00  | 26.67  | 100.00  | 72 ± 15.24 | 73.33  | 46.67  | 100.00  | -0.89 ± 17.19 | 0.00  | -26.67  | 40.00  | 0.849§ |
| Role functioning | 66.67 ± 25.09 | 66.67  | 0.00  | 100.00  | 65.56 ± 23.15 | 66.67  | 16.67  | 100.00  | -1.11 ± 25.43 | 0.00  | -33.33  | 66.67  | 0.725\* |
| Emotional functioning | 66.67 ± 21.73 | 66.67  | 25.00  | 91.67  | 72.22 ± 24.85 | 75.00  | 8.33  | 100.00  | 5.56 ± 23.11 | 8.33  | -58.33  | 41.67  | 0.384§ |
| Cognitive functioning | 76.67 ± 19.05 | 83.33  | 33.33  | 100.00  | 80 ± 17.43 | 83.33  | 33.33  | 100.00  | 3.33 ± 10.89 | 0.00  | -16.67  | 16.67  | 0.729\* |
| Social functioning | 65.56 ± 29.48 | 66.67  | 0.00  | 100.00  | 75.56 ± 22.66 | 83.33  | 33.33  | 100.00  | 10 ± 22.61 | 0.00  | -16.67  | 66.67  | 0.103\* |
| **Symptom scales** |  |  |  | 　 |  |  |  | 　 |  |  |  | 　 |  |
| Fatigue | 38.52 ± 23.61 | 33.33  | 0.00  | 77.78  | 45.93 ± 26.25 | 33.33  | 11.11  | 100.00  | 7.41 ± 23.19 | 11.11  | -44.44  | 66.67  | 0.252§ |
| Nausea and vomiting | 16.67 ± 17.21 | 16.67  | 0.00  | 50.00  | 15.56 ± 16.63 | 16.67  | 0.00  | 50.00  | -1.11 ± 16.63 | 0.00  | -33.33  | 33.33  | 0.748\* |
| Pain  | 34.44 ± 30.71 | 16.67  | 0.00  | 100.00  | 32.22 ± 23.15 | 33.33  | 0.00  | 66.67  | -2.22 ± 30.95 | 0.00  | -66.67  | 33.33  | 0.792§ |
| Dyspnoea | 20 ± 20.37 | 33.33  | 0.00  | 66.67  | 31.11 ± 30.95 | 33.33  | 0.00  | 100.00  | 11.11 ± 19.88 | 0.00  | 0.00  | 66.67  | 0.059\* |
| Constipation  | 37.78 ± 23.93 | 33.33  | 0.00  | 66.67  | 24.44 ± 22.66 | 33.33  | 0.00  | 66.67  | -13.33 ± 20.37 | 0.00  | -66.67  | 0.00  | **0.041\*** |
| Diarrhoea  | 17.78 ± 20.61 | 0.00  | 0.00  | 66.67  | 13.33 ± 20.37 | 0.00  | 0.00  | 66.67  | -4.44 ± 23.93 | 0.00  | -33.33  | 66.67  | 0.492\* |
| Insomnia | 33.33 ± 34.43 | 33.33  | 0.00  | 100.00  | 24.44 ± 19.12 | 33.33  | 0.00  | 66.67  | -8.89 ± 25.72 | 0.00  | -66.67  | 33.33  | 0.141\* |
| Appetite loss | 37.78 ± 40.12 | 33.33  | 0.00  | 100.00  | 28.89 ± 26.85 | 33.33  | 0.00  | 100.00  | -8.89 ± 33.26 | 0.00  | -66.67  | 33.33  | 0.170\* |
| Financial difficulties | 28.89 ± 29.48 | 33.33  | 0.00  | 100.00  | 28.89 ± 29.48 | 33.33  | 0.00  | 66.67  | 0 ± 27.22 | 0.00  | -33.33  | 66.67  | 0.607\* |
| EORTC QLQ-PAN26 (N = 15) |
| **Symptom scales** |  |  |  | 　 |  |  |  | 　 |  |  |  | 　 |  |
| Pancreatic pain | 35.56 ± 28.62 | 33.33  | 0.00  | 100.00  | 23.89 ± 18.48 | 33.33  | 0.00  | 50.00  | -11.67 ± 18.71 | 0.00  | -58.33  | 8.33  | **0.028\*** |
| Bloating | 24.44 ± 25.72 | 33.33  | 0.00  | 66.67  | 28.89 ± 29.48 | 33.33  | 0.00  | 100.00  | 4.44 ± 11.33 | 0.00  | 0.00  | 33.33  | 0.157\* |
| Digestive symptoms | 24.44 ± 22.66 | 16.67  | 0.00  | 66.67  | 40 ± 29.06 | 33.33  | 0.00  | 100.00  | 15.56 ± 18.72 | 0.00  | 0.00  | 50.00  | **0.017\*** |
| Taste | 31.11 ± 28.46 | 33.33  | 0.00  | 100.00  | 33.33 ± 27.22 | 33.33  | 0.00  | 100.00  | 2.22 ± 25.72 | 0.00  | -33.33  | 66.67  | 0.914\* |
| Indigestion | 31.11 ± 28.46 | 33.33  | 0.00  | 66.67  | 31.11 ± 25.72 | 33.33  | 0.00  | 66.67  | 0 ± 17.21 | 0.00  | -33.33  | 33.33  | 0.705\* |
| Flatulence | 33.33 ± 27.22 | 33.33  | 0.00  | 66.67  | 22.22 ± 26.29 | 0.00  | 0.00  | 66.67  | -11.11 ± 23.31 | 0.00  | -66.67  | 33.33  | 0.084\* |
| Weight loss | 22.22 ± 33.7 | 0.00  | 0.00  | 100.00  | 6.67 ± 13.33 | 0.00  | 0.00  | 33.33  | -15.56 ± 29.48 | 0.00  | -66.67  | 33.33  | 0.056\* |
| Weakness arms and legs | 33.33 ± 27.22 | 33.33  | 0.00  | 66.67  | 28.89 ± 26.85 | 33.33  | 0.00  | 100.00  | -4.44 ± 26.85 | 0.00  | -66.67  | 33.33  | 0.262\* |
| Dry mouth | 26.67 ± 21.77 | 33.33  | 0.00  | 66.67  | 35.56 ± 30.95 | 33.33  | 0.00  | 100.00  | 8.89 ± 25.72 | 0.00  | -33.33  | 66.67  | 0.301\* |
| Hepatic symptoms | 20 ± 16.33 | 16.67  | 0.00  | 50.00  | 16.67 ± 16.1 | 16.67  | 0.00  | 66.67  | -3.33 ± 18.46 | 0.00  | -33.33  | 33.33  | 0.510§ |
| Altered bowel habit | 27.78 ± 22.5 | 33.33  | 0.00  | 66.67  | 20 ± 20.37 | 16.67  | 0.00  | 66.67  | -7.78 ± 14.74 | 0.00  | -33.33  | 16.67  | 0.058\* |
| Body image | 38.89 ± 30.23 | 33.33  | 0.00  | 100.00  | 45.56 ± 29.48 | 33.33  | 0.00  | 100.00  | 6.67 ± 15.87 | 0.00  | -33.33  | 33.33  | 0.138§ |
| Troubled with side-effects | 44.44 ± 28.97 | 33.33  | 0.00  | 100.00  | 51.11 ± 26.85 | 33.33  | 0.00  | 100.00  | 6.67 ± 27.76 | 0.00  | -33.33  | 66.67  | 0.618\* |
| Future Worries | 55.56 ± 23.31 | 66.67  | 33.33  | 100.00  | 51.11 ± 29.48 | 33.33  | 0.00  | 100.00  | -4.44 ± 29.48 | 0.00  | -66.67  | 66.67  | 0.459\* |
| Planning of activities | 44.44 ± 28.97 | 33.33  | 0.00  | 100.00  | 33.33 ± 29.81 | 33.33  | 0.00  | 100.00  | -11.11 ± 28.97 | 0.00  | -66.67  | 33.33  | 0.146\* |
| **Functional scales** |  |  |  | 　 |  |  |  | 　 |  |  |  | 　 |  |
| Satisfaction with health care | 43.33 ± 29.69 | 33.33  | 0.00  | 100.00  | 47.78 ± 33.26 | 33.33  | 0.00  | 100.00  | 4.44 ± 32.47 | 0.00  | -66.67  | 50.00  | 0.617§ |
| Sexuality | 74.44 ± 33.81 | 100.00  | 0.00  | 100.00  | 57.78 ± 37.94 | 66.67  | 0.00  | 100.00  | -16.67 ± 49.81 | 0.00  | -100.00  | 66.67  | 0.231\* |

Change, Last visit – Baseline visit (visit 2). QOL, quality of life; EORTC, European Organization for Research and Treatment of Cancer; QLQ-C30, Quality of Life Questionnaire Core 30; QLQ-PAN26, Quality of Life Questionnaire pancreatic cancer module 26; SD, standard deviation; Min, minimum; Max, maximum. § Paired t-test. \* Wilcoxon signed rank test.